Saturday 17 October 2026
Export CTEV’s income statement to Excel — free account
Claritev Corporation
CTEV Healthcare Health Information Services
Claritev Corporation’s revenue for fiscal 2025 (year ended December 2025) was $965.4 million, up 3.74% from fiscal 2024. In the quarter to June 2026, revenue grew 6.59%, EPS grew 8.40%, free cash flow grew 49.1% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
22.12
1.74
−7.29%
Follow CTEV
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.92 | 0.73 | 0.28 | 0.58 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
44.06 | 10.60 | (5.96) | 6.24 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.74 | 5.46 | 5.06 | 5.25 | |
EV/EBITDA |
12.20 | 10.92 | 10.30 | 10.75 | |
EV/Operating CF |
309.53 | 44.91 | 48.74 | 39.27 | |
EV/FCF |
(48.49) | (429.21) | (137.93) | (291.44) | |
Quick Ratio |
0.83 | 0.60 | 0.93 | 0.67 | |
Current Ratio |
1.21 | 0.86 | 1.28 | 1.00 | |
Net Debt/EBITDA |
37.05 | 43.01 | 39.05 | 34.09 | |
Debt/Assets |
92.81% | 94.00% | 97.41% | 98.09% | |
Debt/Equity |
(45.48) | (27.49) | (20.11) | (16.23) | |
Asset Turnover |
0.18 | 0.19 | 0.20 | 0.20 | |
Operating CF/Net income |
(0.28) | (0.82) | 0.62 | (1.56) | |
Capex/Depreciation |
(0.32) | (0.26) | (0.41) | (0.34) | |
Interest Coverage |
0.10 | (0.08) | 0.07 | 0.23 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
25.16% | 24.96% | 23.64% | 21.51% | |
Intangible Assets out of Total Assets |
0.88 | 0.88 | 0.87 | 0.86 | |
Share Based Compensation of Revenue |
2.84% | 3.16% | 2.82% | 2.86% | |
Graham Net Nets |
(5.53) | (6.88) | (17.71) | (8.32) | |
Graham Number |
53.92 | 62.92 | 74.00 | 80.58 | |
Earnings Yield |
(39.39%) | (40.47%) | (106.06%) | (49.87%) | |
Free Cash Flow Yield |
(12.86%) | (1.75%) | (13.16%) | (3.10%) | |
Revenue per Share |
14.92 | 15.00 | 14.66 | 15.18 | |
Operating CF per Share |
1.20 | 4.03 | (2.74) | 5.46 | |
Capex per Share |
(2.20) | (1.82) | (2.80) | (2.24) | |
Free Cash Flow per Share |
(0.99) | 2.21 | (5.54) | 3.22 | |
Cash per Share |
3.07 | 1.72 | 2.08 | 1.63 | |
Shareholders Equity per Share |
(6.18) | (10.17) | (14.04) | (16.97) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(6.18) | (10.17) | (14.04) | (16.97) | |
Free Cash Flow |
(16.35) | 36.38 | (92.55) | 54.59 | |
Working Capital |
44.14 | (36.99) | 52.70 | (1.09) | |
Capital Expenditures |
(36.20) | (29.91) | (46.77) | (38.08) | |
Net Current Asset Value |
(4,834.68) | (4,831.27) | (4,831.45) | (4,815.28) | |
EV/EBIT |
0.00 | 183.19 | 192.97 | 160.77 | |
Capex to Sales |
0.15 | 0.12 | 0.19 | 0.15 | |
Price to Operating Income |
0.00 | 24.43 | 10.63 | 17.81 | |
| Other line items | |||||
Average Receivables |
104.56 | 108.69 | 117.19 | 127.24 | |
Average Payables |
30.74 | 73.40 | 46.84 | 50.05 | |
Average Assets |
5,154.75 | 5,019.64 | 4,961.91 | 4,917.92 | |
Average Common Equity |
52.86 | (41.58) | (109.79) | (163.87) |
Columns are period end dates